Literature DB >> 1460355

Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II. A review.

S Spitzer1, R Bach, H Schieffer.   

Abstract

On the basis of the present studies physical therapy is the most effective basis therapy of peripheral arterial occlusive disease stage II according to Fontaine. The consequent integration of the patients into widespread vascular training groups would be desirable. All present studies with so-called vasoactive drugs led to a statistically significant increase in pain-free walking distance. This is especially true for the substances naftidrofuryl, pentoxifylline, and buflomedil. Nevertheless, these studies do not fully meet the standards set by the GCP or the FDA guidelines. It must also be said that the increase in walking distance by vasoactive substances is less pronounced than the effect obtained by walk training alone. Both the vasoactive therapy and controlled walk training aim at an increase in pain-free walking distance. It is, however, still unclear whether the modes of therapy described influence the primary disease. Angiographically controlled studies are momentarily not available.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1460355

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  3 in total

Review 1.  Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

2.  Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.

Authors:  S C Hood; D Moher; G G Barber
Journal:  CMAJ       Date:  1996-10-15       Impact factor: 8.262

Review 3.  Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data.

Authors:  T De Backer; R Vander Stichele; P Lehert; L Van Bortel
Journal:  BMJ       Date:  2009-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.